Developing Pharmaceutical Markets - Central and Eastern European

Questions: Discounts, Updates etc.

Pages: 97

Price (Single): £1,999

Price (Departmental): £3,999

Price (Company): £5,999

Publication Date: 2006-11-23

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


This report discusses prospects for the large developing market of Central and Eastern Europe.

Central and Eastern European Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Central and Eastern European Developing Markets for Pharmaceuticals, 2006-2011, concentrates on the following themes:

Why you should buy this report: 

- Competitive characteristics of the market, both at national and regional level
- Regulatory, technological, societal and political issues
- Drivers and restraints
- Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets. That situation will provide one of the greatest opportunities currently available to the international pharmaceutical industry. Many developing countries have strongly growing economies; that factor constitutes a driving force in the reform and broadening of healthcare systems. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic products. Private healthcare will undergo similar developments.

Manufacturers of pharmaceuticals are currently working hard to address unmet healthcare needs in developing countries. By doing so, they are making better treatments available to millions of patients and improving the overall performance of their companies.

Table of Contents

 

  • List of Tables
  • Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
  • Table 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
  • Table 2.3 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2005
  • Table 2.4 How the Top 10 Markets Compared With The Rest of the World, 2005
  • Table 2.5 World Pharmaceutical Revenues ($bn) by Region, 2005
  • Table 2.6 Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005
  • Table 2.7 Combined Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005
  • Table 2.8 A SWOT Analysis for Developing Pharmaceutical Markets, 2006-2011
  • Table 2.9 The 10 Most Populous Countries - 2005 and 2030 Compared
  • Table 3.1 Pharmaceutical Revenues ($bn) for Russia, 2005-2011
  • Table 3.2 Russia: Fundamental Demographics and Healthcare Economics
  • Table 4.1 Revenues ($bn) for Leading Markets in Central and Eastern Europe, 2005-2011
  • Table 4.2 Pharmaceutical Revenues ($bn) for Poland, 2005-2011
  • Table 4.3 Poland: Fundamental Demographics and Healthcare Economics
  • Table 4.4 Pharmaceutical Revenues ($bn) for Hungary, 2005-2011
  • Table 4.5 Hungary: Fundamental Demographics and Healthcare Economics
  • Table 4.6 Pharmaceutical Revenues ($bn) for the Czech Republic, 2005-2011
  • Table 4.7 Czech Republic: Fundamental Demographics and Healthcare Economics
  • Table 5.1 The Leading Developing Markets Ranked in Order of Potential Revenue Generation ($bn), 2011
  • Table 5.2 Developing Markets Ranked by Growth Rate (CAGR %), 2005-2011
  • Table 5.3 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
  • Table 5.4 Share (%) of the World Market by Developing Region, 2005-2011

  • List of Figures
  • Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
  • Figure 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
  • Figure 2.3 World Pharmaceutical Revenues ($bn) by Region, 2005
  • Figure 2.4 World Market Share (%) by Region, 2005
  • Figure 2.5 Growth Rates (%) from Previous Year by Region, 2005
  • Figure 2.6 The Increasing Average Cost ($m) of NME Development, 1976-2005
  • Figure 3.1 Pharmaceutical Revenues ($bn) for Russia, 2005-2011
  • Figure 3.2 World Market Share (%) for Russia - 2005 and 2011 Compared
  • Figure 3.3 A Break-down (%) of the Russian Prescription Drug Market by Type of Sales ($m), 2005
  • Figure 3.4 Leading Companies in the Russian Retail Pharmaceutical Market ($m), 2005
  • Figure 3.5 Leading Companies in the Russian Hospital Pharmaceutical Market ($m), 2005
  • Figure 3.6 Leading Russian Pharmaceutical Companies ($m), 2005
  • Figure 3.7 Leading Therapeutic Areas ($m) In the Russian Pharmaceutical Market, 2005
  • Figure 4.1 Revenues ($bn) for Leading Markets in Central and Eastern Europe, 2005-2011
  • Figure 4.2 Combined Revenues ($bn) for Leading Markets in Central and Eastern Europe, 2005-2011
  • Figure 4.3 Growth Rates (% CAGR) for the CEE Markets, 2005-2011
  • Figure 4.4 Pharmaceutical Revenues ($bn) for Poland, 2005-2011
  • Figure 4.5 World Market Share (%) for Poland - 2005 and 2011 Compared
  • Figure 4.6 Pharmaceutical Revenues ($bn) for Hungary, 2005-2011
  • Figure 4.7 World Market Share (%) for Hungary - 2005 and 2011 Compared
  • Figure 4.8 Pharmaceutical Revenues ($bn) for the Czech Republic, 2005-2011
  • Figure 4.9 World Market Share (%) for the Czech Republic - 2005 and 2011 Compared
  • Figure 5.1 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
  • Figure 5.2 Revenues ($bn) for Leading Markets of Developing Regions Combined, 2005-2011
  • Figure 5.3 Share (%) of the World Market by Developing Region, 2005-2011
  • Figure 5.4 Share (%) of the World Market by Developing Regions Combined, 2005-2011
  •  

    Other users found this report page using the following search terms: russia pharmaceutical markets pharmaceutical market europe eastern markets central european pharma industry pharmaceuticals

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.

    All reports are subject to copyright